Needham Maintains Buy on Cardlytics, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Kyle Peterson maintains a Buy rating on Cardlytics (CDLX) but lowers the price target from $17 to $12.

May 09, 2024 | 10:49 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham maintains a Buy rating on Cardlytics but lowers the price target from $17 to $12.
While the maintenance of a Buy rating suggests continued confidence in the company's fundamentals, the reduction in price target could indicate a reassessment of the company's short-term growth prospects or market conditions. This mixed signal might lead to neutral short-term price movement as investors digest both the continued endorsement and the lowered expectations.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100